Abstract: Provided herein are methods for identifying a risk of low BMD in a subject, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating low BMD-related disorders, such as osteoporosis, and therapeutic and preventative methods applicable to osteoporosis. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome.

Abstract: Polymorphic A-kinase anchor proteins (AKAPs) and nucleic acids encoding the proteins are provided herein. Methods of detecting polymorphic AKAPs and nucleic acids encoding the AKAPs, and kits for use in the detection methods are also provided. Further provided herein are methods of identifying subjects having or at risk of developing diseases or disorders, such as those related to signal transduction and/or cardiovascular disease. Methods of determining susceptibility to morbidity and/or increased or early mortality are also provided.

Abstract: Provided herein are methods for identifying risk of breast cancer in a subject and/or a subject at risk of breast cancer, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating breast cancer, and therapeutic methods for treating breast cancer in a subject. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome.

Abstract: Provided herein are methods for identifying risk of breast cancer in a subject and/or a subject at risk of breast cancer, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating breast cancer, and therapeutic methods for treating breast cancer in a subject. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome.

Abstract: Provided herein are methods for identifying risk of melanoma in a subject and/or subjects at risk of melanoma, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating melanoma, therapeutic methods for treating melanoma in a subject and compositions comprising one or more melanoma cells and one or more NRP1, NID2, ENDO180, CDK10, FPGT, CARK, PCLO or REPS2 directed agents. These embodiments are based upon an analysis of polymorphic variations in a NRP1, NID2, ENDO180, CDK10, FPGT, CARK, PCLO or REPS2 nucleic acid, exemplified by nucleotide sequences of SEQ ID NO: 1-17.

Abstract: Provided herein are methods for identifying risk of breast cancer in a subject and/or a subject at risk of breast cancer, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating breast cancer, and therapeutic methods for treating breast cancer in a subject. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome.

Abstract: Provided herein are methods for identifying risk of breast cancer in a subject and/or a subject at risk of breast cancer, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating breast cancer, and therapeutic methods for treating breast cancer in a subject. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome.

Abstract: Provided herein are methods for identifying risk of melanoma in a subject and/or subjects at risk of melanoma, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating melanoma, therapeutic methods for treating melanoma in a subject and compositions comprising one or more melanoma cells and one or more CDK10, FPGT, PCLO or REPS2 directed agents. These embodiments are based upon an analysis of polymorphic variations in a CDK10, FPGT, PCLO or REPS2 nucleic acid, exemplified by nucleotide sequences of SEQ ID NO: 1, 2, 3 or 4.

Abstract: Provided herein are methods for identifying a risk of cancer in a subject and/or a subject at risk of cancer, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating cancer, and therapeutic methods for treating cancer in a subject. These embodiments are based upon an analysis of polymorphic variations in a KLF12 nucleic acid, which has a nucleotide sequence exemplified in SEQ ID NO: 1, 2 or 3.

Abstract: Provided herein are methods for identifying risk of melanoma in a subject and/or subjects at risk of melanoma, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating melanoma, therapeutic methods for treating melanoma in a subject and compositions comprising one or more melanoma cells and one or more NRP1, NID2 or ENDO180 directed agents. These embodiments are based upon an analysis of polymorphic variations in a NRP1, NID2 or ENDO180 nucleic acid, exemplified by nucleotide sequences of SEQ ID NO: 1, 2 or 3.

Abstract: Provided herein are methods for identifying a subject at risk of breast cancer, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating breast cancer, and therapeutic methods for treating breast cancer in a subject. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome.

Abstract: Provided herein are methods for identifying a subject at risk of melanoma and risk of melanoma in a subject, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating melanoma, and therapeutic methods for treating melanoma in a subject. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome.

Abstract: Provided herein are methods for identifying risk of breast cancer in a subject and/or a subject at risk of breast cancer, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating breast cancer, and therapeutic methods for treating breast cancer in a subject. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome.